Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

499
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
499
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

135
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
135
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

122
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
122
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs01:20

Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs

129
Body:Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to...
129
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

307
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
307

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Contemporary Clinical Practices in Korean Patients With Coronary Chronic Total Occlusion: Results From the K-CTO Nationwide Retrospective Registry.

Korean circulation journal·2026
Same author

Metabolic and Safety Outcomes of Statin-Ezetimibe Versus High-Intensity Statin in Older Patients.

Journal of the American Heart Association·2026
Same author

Systemic blood pressure changes following coronary revascularization: towards a coronary baroreflex?

European heart journal open·2026
Same author

Phenotypic clustering identifies heterogeneous cardiovascular risk among patients with elevated lipoprotein(a).

Scientific reports·2026
Same author

Efficacy and Safety of Fimasartan/Indapamide Combination Therapy versus Fimasartan Monotherapy in Patients with Essential Hypertension Inadequately Responding to Fimasartan 30 mg (FINEDUO): A Randomized, Double-Blind, Multicenter, Phase III Study.

Drug design, development and therapy·2026
Same author

Visit-to-visit systolic blood pressure variability and risk of severe hypertensive episodes in a multicenter cohort.

American journal of hypertension·2026

Related Experiment Video

Updated: Dec 11, 2025

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

4.1K

Immediate vs Delayed Stenting in ST-Elevation Myocardial Infarction: Rationale and Design of the International

E Marc Jolicoeur1, Nandini Dendukuri2, Patrick Belisle3

  • 1Montreal Heart Institute, Université de Montréal, Montréal, Québec, Canada.

The Canadian Journal of Cardiology
|August 18, 2020
PubMed
Summary

Delayed stenting may improve outcomes for ST-elevation myocardial infarction (STEMI) patients by reducing cardiovascular events. This strategy contrasts with immediate stenting, aiming to prevent complications from thrombus-laden arteries.

More Related Videos

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.4K
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.6K

Related Experiment Videos

Last Updated: Dec 11, 2025

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

4.1K
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.4K
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.6K

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Clinical Trials

Background:

  • Primary percutaneous coronary intervention (PCI) restores blood flow but immediate stenting in thrombus-laden arteries can cause embolization, impairing reperfusion.
  • The benefit of delayed stenting versus immediate stenting in ST-elevation myocardial infarction (STEMI) remains uncertain.

Purpose of the Study:

  • To compare outcomes of delayed versus immediate stenting in STEMI patients.
  • To assess the prevention of cardiovascular death, myocardial infarction, heart failure, or revascularization at 9 months.

Main Methods:

  • The Primary Reperfusion Secondary Stenting (PRIMACY) trial is a Bayesian prospective, randomized, open-label, blinded endpoint study.
  • Participants with STEMI were randomized to immediate stenting or delayed stenting (24-48 hours) bridged with antithrombin therapy.
  • Bayesian analysis will combine PRIMACY data with existing trials (DEFER, MIMI, DANAMI-3, INNOVATION) for robust efficacy assessment.

Main Results:

  • 305 participants were randomized across 15 centers in France and Canada (April 2014-September 2017).
  • Baseline characteristics included a median age of 59 years, 81% male, and 3% prior PCI history.
  • Results will be updated with patient-level data from 1568 participants in four prior trials.

Conclusions:

  • The study aims to determine if delayed stenting safely reduces adverse cardiovascular endpoints compared to immediate stenting in STEMI patients.
  • Clarifying the optimal stenting strategy is crucial for improving STEMI patient outcomes.